Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 17, Issue 4, 1999, Pages 1095-1104

  Eckhardt MD, S Gail ^a   Rizzo, Jinee ^a   Sweeney, Kevin R ^a   Cropp, Gillian ^a   Baker, Sharyn D ^a   Kraynak, Maura A ^a   Kuhn, John G ^a   Villalona Calero, Miguel A ^a   Hammond, Lisa ^a   Weiss, Geoffrey ^a   Thurman, Allison ^a   Smith, Lon ^a   Drengler, Ronald ^a   Eckardt, John R ^a   Moczygemba, Judy ^a   Hannah, Alison L ^a   Von Hoff, Daniel D ^a   Rowinsky, Eric K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEFLUNOMIDE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOLID TUMOR; VOMITING;

EID: 0032940051     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.4.1095     Document Type: Article

References (23)

1. Shawver L, Schwartz DP, Mann E, et al: Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide. Clin Cancer Res 3:1167-1177, 1997
2. SU101 [Clinical Investigator's Brochure]. Redwood City, CA, Sugen, Inc, 1998
3. Westermark B, Heldin CH: Perspectives in cancer research: Platelet-derived growth factor in autocrine transformation. Cancer Res 51:5087-5092, 1991
4. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-209, 1990
5. Schlessinger J, Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron 9:383-391, 1992
6. Shawver LK, Strawn LM, Ullrich A: Membrane bound receptor tyrosine kinases and chemical carcinogenesis. Mutat Res 333:23-28, 1995
7. Doolittle RF, Hunkapiller MW, Hood LE, et al: Simian sarcoma virus oncogene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science 221:275-277, 1983
8. sis of simian sarcoma virus. Nature 304:35-39, 1983
9. Nister M, Claesson-Welsh L, Eriksson A, et al: Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 266:16755-16763, 1991
10. Nister M, Libermann TA, Betsholtz C, et al: Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines. Cancer Res 48:3910-3918, 1988
11. Ebert M, Yokoyama M, Friess H, et al: Induction of platelet-derived growth factor a and b chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer 62:529-535, 1995
12. Coltrera MD, Wang J, Porter PL, et al: Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor beta subunit in human breast tissue and breast carcinoma. Cancer Res 55:2703-2708, 1995
13. Hermanson M, Funa K, Hartman M, et al: Platelet-derived growth factor and its receptors in human glioma tissue: Expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52:3213-3219, 1992
14. Antoniades HN, Galanopoulos T, Neville-Golden J, et al: Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc Natl Acad Sci USA 89:3942-3946, 1992
15. Brouty-Boye D, Magnien V: Myofibroblast and concurrent ED-beta fibronectin phenotype in human stromal cells cultured from non-malignant and malignant breast tissue. Eur J Cancer 30A:66-73, 1994
16. Ponten F, Ren Z, Nister M, et al: Epithelial-stromal interactions in basal cell cancer: The PDGF system. Invest Dermatol 102:304-309, 1994
17. Forsberg K, Valyi-Nagy I, Heldin CH, et al: Platelet-derived growth factor (PDGF) in oncogenesis: Development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 90:393-397, 1993
18. Nair RV, Cao W, Morris RE: Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine. Immunol Lett 47:171-174, 1995
19. Greene S, Watanabe K, Braatz-Trulson J, et al: Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 50:861-867, 1995
20. Williamson RA, Yea CM, Robson PA, et al: Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Transplant Proc 28:3088-3091, 1996
21. Xu X, Williams JW, Gong H, et al: Two activities of the immunosuppressive metabolite of leflunomide: Inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation. Biochem Pharmacol 52:527-534, 1996
22. Shawver LK, Sutton B, West KA, et al: The antitumor efficacy of SU101 in human tumor models is exerted by the parent compound and not the metabolite. Proc Am Assoc Cancer Res 39:2185, 1998 (abstr)
23. Mladenovic V, Domljan Z, Rozman B, et al: Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 38:1595-1603, 1995